90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 42-45

  Hoffmann, Martha ^a   Troch, Marlene ^a   Eidherr, Harald ^a   Traub Weidinger, Tatjana ^a   Jonak, Constanze ^b   Muellauer, Leonhard ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

90Y ibritumomab tiuxetan; MALT lymphoma; rituximab

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; CD20 ANTIGEN; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; DISSEMINATED CANCER; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; LEUKOPENIA; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; THROMBOCYTOPENIA; FEMALE; IMMUNOLOGY; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; PATHOLOGY; RADIOIMMUNOTHERAPY; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 78651312178     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.534519     Document Type: Article

References (13)

1. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 214-217.
2. Isaacson PG, Du MQ. MALT lymphoma-from morphology to molecules. Nat Rev Cancer 2004;4:644-653.
3. Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa associated lymphoid tissue lymphoma using extensive staging: a single center experience. J Clin Oncol 2006;24:3136-3141.
4. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
5. Martinelli G, Laszlo D, Ferreri A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.
6. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-310.
7. Raderer M, Wöhrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincris-tine, and prednisolone in patients with relapsed MALT lymphoma. Oncology 2006;70:411-417.
8. Salar A, Domingo-Domenech E, Estary C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-5217.
9. Illidge T, Chan C. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma 2008;49:1263-1273.
10. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiux-etan compared with no addtional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
11. Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90-ibritumomab tiux-etan (Zevalin) for front line treatment of early stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009;20:709-714.
12. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J Nucl Med 2008;11:12-15.
13. Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010;34:184-189.